Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe
PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data
London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC).
'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.'
PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies.
The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe.
For further information, contact:
Purespring:
Peter Mulcahycontact@purespringtx.com+44 (0)20 3855 6324LinkedIn
ICR Healthcare
Amber Fennell, Sarah Elton-Farrpurespring@icrhealthcare.com
Notes to Editors
About Purespring
Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas.
Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases.
The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases.
Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery.
Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date.
For more information please visit: purespringtx.com and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Pacific microstate sells first passports to fund climate action
A remote Pacific nation has started selling passports to fund climate action, but is so far struggling to attract new citizens to the low-lying, largely barren island. Pacific microstate Nauru, one of the world's smallest nations, has a novel plan to fund its fight against climate change by selling so-called "golden passports". Selling for US$105,000 each, Nauru plans to drum up more than US$5 million in the first year of the "climate resilience citizenship" programme. Almost six months after the scheme opened in February, Nauru has so far approved just six applications -- covering two families and four individuals. Despite the slow start -- Nauru eventually hopes to sell 66 passports in the scheme's first year -- President David Adeang remained upbeat. "We welcome our new citizens whose investment will assist Nauru to secure a sustainable and prosperous future for generations to come," he told AFP on Thursday. Nauru believes the passport programme could eventually generate $43 million -– or about 500 successful applicants -- which would account for almost 20 percent of total government revenue. But there are fears the scheme could be ripe for exploitation. Edward Clark, who runs Nauru's climate passport programme, said one application has already been withdrawn after officials flagged "adverse findings" during background checks. "The application would have been rejected had it not been withdrawn," he told AFP. A previous Nauru attempt to sell passports ended in disaster. In 2003, Nauru officials sold citizenship to Al-Qaeda members who were later arrested in Asia. Among the first batch of climate passports approved was an unnamed German family of four living in Dubai, said Clark touting the "major milestone". - 'Political volatility' - "They were looking for a second citizenship to provide them with a Plan B given the current global political volatility." The Nauru passport provides visa-free entry into 89 countries, including the United Kingdom, Ireland, United Arab Emirates and Hong Kong. More than 60 different nations offer some form of migration for investment schemes, Australia's Lowy Institute has found. Pacific nations such as Vanuatu, Samoa and Tonga have all dabbled in selling passports. The island republic of Nauru sits on a small plateau of phosphate rock in the sparsely populated South Pacific. With a total landmass of just 21 square kilometres (eight square miles), it is one of the world's smallest nations. Unusually pure phosphate deposits -- a key ingredient in fertiliser -- once made Nauru one of the wealthiest places, per capita, on the planet. But these supplies have long dried up, and researchers today estimate 80 percent of Nauru has been rendered uninhabitable by mining. What little land Nauru has left is threatened by encroaching tides. Scientists have measured sea levels rising 1.5 times faster than global averages. Nauru will eventually need to relocate 90 percent of its population as creeping seas start to eat away at its coastal fringe. The first phase of this mass relocation is estimated to cost more than $60 million. lec/sft/tc
Yahoo
32 minutes ago
- Yahoo
UK warned it risks exodus of 'disillusioned' doctors
Nearly one in five doctors is considering quitting in the UK, new figures show, while one in eight is thinking about leaving the country to work abroad. The General Medical Council (GMC), which commissioned the research, is warning that plans to cut hospital waiting lists will be at risk unless more is done to retain them. By July 2029, the prime minister has said 92% of patients needing routine hospital treatment like hip and knee replacements will be . "[Poor staff retention] could threaten government ambitions to reduce waiting times and deliver better care to patients," warned the authors of the GMC's latest report. The main reason doctors gave for considering moving abroad was they are "treated better" in other countries, while the second most common reason was better pay. Some 43% said they had researched career opportunities in other countries, while 15% reported taking "hard steps" towards moving abroad, like applying for roles or contacting recruiters. "Like any profession, doctors who are disillusioned with their careers will start looking elsewhere," said Charlie Massey, chief executive of the GMC. "Doctors need to be satisfied, supported, and see a hopeful future for themselves, or we may risk losing their talent and expertise altogether." Read more on Sky News:Airport reopens after plane incidentReeves told big tax rises neededHiroshima survivor's warning, 80 years on The report - which comes after a recent five-day walkout by resident doctors - is based on the responses of 4,697 doctors around the UK and also explores how they feel about career progression. One in three said they are unable to progress their education, training and careers in the way they want. Those who didn't feel like their careers were progressing were at higher risk of burnout and were less satisfied with their work. The GMC blamed workloads, competition for jobs, and lack of senior support for development for adversely impacting the career progression of UK doctors. 'Legitimate complaints' The Department of Health and Social Care acknowledged doctors had suffered "more than a decade of neglect". "Doctors have legitimate complaints about their conditions, including issues with training bottlenecks and career progression," said a spokesperson. "We want to work with them to address these and improve their working lives, which includes our plans set out in the 10 Year Health Plan to prioritise UK graduates and increase speciality training posts. "This government is committed to improving career opportunities and working conditions, bringing in ways to recognise and reward talent - as well as freeing up clinicians' time by cutting red tape."
Bloomberg
34 minutes ago
- Bloomberg
Sony Lifts Outlook on Entertainment Demand Despite Tariff Threat
Sony Group Corp. raised its earnings forecast on Thursday after a strong showing from its entertainment divisions that outweighed the threat of new US tariffs on chips. The Tokyo company now expects operating profit for the year ending March to be ¥1.33 trillion ($9 billion), versus the average of analyst estimates of ¥1.39 trillion. Back in May, in the midst of uncertainty around Washington's new import tax regime, Sony had warned its profit would take a ¥100 billion hit and set its forecast at ¥1.28 trillion. It said it now sees a tariff impact of around ¥70 billion on its operating income.
